No, my site did not get overrun by the pharmaceutical pushers that like to submit “advice” in the comments section. The title is referring to…
Today I was playing around with my shiny new toy — the BigPatentData Portfolio Visualizer1 — and made a video that I think provides an…
My oversight last week had me wondering how common nonpublication requests are. I couldn’t find this stat in any of they USPTO’s dashboards nor anywhere else…
As is a recurring theme on this blog, my readers have led me back from darkness into the light. In response to yesterday’s post, Harry Vartanian pointed…
Update Feb 28, 2019: The allowance rates were in fact probably not this high. I failed basic patent law history as explained here. This week…
It should surprise no one that I think examiner statistics are useful (otherwise why would I waste time blogging about them or building BigPatentData Examiner…
I ended my last post saying that there was a bunch of “ho hum” opinions that I would get to later. Turns out after a…
Okay, I know last week I said I wouldn’t blog about every PTAB opinion citing to the 2019 Revised Subject Matter Eligibility Guidance, but turns…
Okay, I promise I am not going to blog about every PTAB opinion mentioning the 2019 Guidance, but this one has to be seen to…
Update 2/7/2019: an even better opinion is out. See here. Turns out yesterday’s post missed a seventh PTAB opinion that cites to the 2019 Revised…